Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study is designed to be a pivotal trial that could potentially support a United States regulatory filing for AC220 to address a targeted AML patient population with the internal tandem duplication (ITD) activating mutation for FLT3.

"Based on the promising results of our first-in-human clinical trial presented at the American Society of Hematology (ASH), we are pleased to advance AC220 into this important Phase 2 study in AML. We are deeply grateful to our investigators, their staff, and their patients, as well as our entire team at Ambit, for their vital contributions in achieving this significant milestone," said Wendell Wierenga, EVP of Research and Development at Ambit. "If the ACE study is successful, AC220 could emerge as the first once-a-day, orally available targeted therapy for AML patients. Over the next several months we plan to initiate additional clinical trials with AC220 to support the potential registration in AML, and to explore its utility in certain types of solid tumors."

"AML is a devastating disease for which few treatment options exist," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and principal investigator for the ACE Study. "There are no treatments currently approved by the FDA that specifically target the activating ITD mutations of the FLT3 kinase, present in 2
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Superdome and Denver,s Coors Field ... 17, and coincide with hemophilia community events in a dozen ...
(Date:4/16/2015)... April 16, 2015 ... pharmaceutical investment and R&D group, and Lancet, ... research, development and commercialization of new medicines ... the intention to stimulate the innovative development ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, ... to improving cancer surgeries, announced today that it has ... cancer illuminator, AVB-620, in women with primary, non-recurrent breast ... company also welcomed the addition of Steven Chen ... The open label, dose escalation study will enroll ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Fairleigh ... Joseph V. Gulfo to become the Executive Director ... Simultaneously, FDU announced the kick-off of the Initiative ... spearheaded by Dr. Gulfo, under the Rothman Institute ... of Business) and in collaboration with FDU’s School ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... 18 Premier Research Group plc (AIM:,PRG) announces ... Vice President,Global Human Resources. Mr. Keenen will be ... related to maximizing the,effectiveness of Premier Research,s people ... Dr. Troy McCall, COO, commented: "We are ...
... Ultra-low power DSP core from CEVA provides unmatched ... for state-of-the-art cochlear implant system, SAN JOSE, ... ; LSE: CVA), a leading licensor of innovative ... wireless, consumer and,multimedia applications, today announced that Advanced ...
... TOKYO, September 18 Sosei Group Corporation,("Sosei"; TSE ... AD 337, an enantiomer of an approved, centrally ... of principle trial,for the treatment of fibromyalgia syndrome ... placebo,controlled, parallel group exploratory study, investigated the efficacy,safety ...
Cached Biology Technology:Premier Research Appoints Global Head of Human Resources 2Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System 2Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System 3Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome 2
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... new study by researchers at the University of California, ... that promoting cleaner, more efficient technologies for producing charcoal ... significant climate change and development benefits. , The African ... and Latin America, is dependent on both wood and ...
... Linus Pauling's book Vitamin C and The Common Cold, published ... believe in the value of the vitamin for cold prevention ... reviewing all of the best clinical research on this topic, ... unjustified. , Robert M Douglas of the Australian National University, ...
... critical piece of synapse-associated protein 97 (SAP97) found in abundance ... play a role in everything from cardiac contractions to memory ... , Dale Mierke, associate professor of medical science at Brown, ... is an important step. Now that part of the protein's ...
Cached Biology News:Study of energy and health in Africa focuses spotlight on charcoal and forest management 2Study of energy and health in Africa focuses spotlight on charcoal and forest management 3Does vitamin C help prevent or treat the common cold? Maybe not, after all. 2Researchers reveal secret of key protein in brain and heart function 2
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
...
Biology Products: